173522-96-8 Lamivudine salicylate AKSci R836
 
 
Loading Please Wait...
  R836    AKSci Bulk Reagent
Lamivudine salicylate
, 98% (HPLC)
 



IDENTITY
CAS Number:173522-96-8
MDL Number:MFCD09751000
MF:C8H11N3O3S.C7H6O3
MW:367.38
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:138-143°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Application(s):Reverse transcriptase inhibitor; Zalcitabine analog
Form:Salicylate salt

REVIEW

 Lamivudine is a potent, single enantiomer nucleoside analog reverse-transcriptase inhibitor (NRTI) antiviral drug. It has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV. Long-term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus (YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated. Lamivudine is an analog of cytidine and can inhibit both types of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. It is phosphorylated intracellularly to lamivudine triphosphate, which competes for incorporation into viral DNA. It inhibits HIV reverse transcriptase and HBV polymerase enzymes competitively and acts as a chain terminator of DNA synthesis. The lack of a 3''-OH group in the incorporated nucleoside analog prevents the formation of the 5'' to 3'' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

REFERENCES
[1]Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD: A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther. 2006;11(6):761-70.
[2] Goodyear, Michael David; Dwyer, P. Owen; Hill, Malcolm Leithead; Whitehead, Andrew Jonathan; Hornby, Roy; Hallett, Peter Diastereoselective synthesis of oxathiolane nucleoside analogs. PCT Int. Appl. (1995), WO 9529174 A1 19951102.
[3] Shah, Chirag Surendrabhai; Sorathiya, Suresh Devjibhai; Agarwal, Virendra Kumar; Nirogi, Venkata Satya Ramakrishna; Pandita, Kanwal; Patel, Pankaj Ramanbhai Process for the preparation of crystalline polymorph II of lamivudine PCT Int. Appl. (2003), WO 2003027106 A1 20030403.
[4] Katlama C, Havlir DV.Newer nucleosides: lamivudine and stavudine. AIDS. 1996;10 Suppl A:S135-43.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
R836Lamivudine salicylate
G890Lamivudine

Current as of October 15, 2024


Download SDS Request COA

All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Antivirals, Antiretrovirals, NRTIs


PubChem
  @PubMed